FTC Announces Agenda for November 8 Workshop on Examining Competition Issues Related to Prescription Drug Markets
The Unified Framework for Tax Reform that is supported by President Trump will mean hardworking Americans can keep more of their money. The average American household income could increase between $4,000 and $9,000 a year in wages and salary alone by cutting the Federal corporate income tax rate from 35 percent to 20 percent, according to an analysis by the Council of Economic Advisors (CEA). “Lower taxes on American business means higher wages for American workers, and it means more products made right here in the USA.” – President Donald J. Trump
-------------
President Trump Urges Optimism, Hope for America’s Future
Last night, President Trump delivered the keynote address at The Heritage Foundation’s annual President’s Club Meeting. The President encouraged all Americans to have confidence in the future of our Nation and immense pride in our history. President Trump drew attention to the once-in-a-generation opportunity to make history by fighting for pay raises for all Americans through tax reform and investing in American businesses and jobs.
Last night, President Trump delivered the keynote address at The Heritage Foundation’s annual President’s Club Meeting. The President encouraged all Americans to have confidence in the future of our Nation and immense pride in our history. President Trump drew attention to the once-in-a-generation opportunity to make history by fighting for pay raises for all Americans through tax reform and investing in American businesses and jobs.
Vice President Talks Tax Relief in Buffalo, NY
Vice President Mike Pence traveled to Buffalo, New York, on Tuesday to talk about the Administration’s America first tax relief plan with local businesses, community leaders, and families. The current tax code is broken and burdensome on American taxpayers and job-creators. The new plan will provide middle-class tax relief by permanently reducing tax rates, restoring the competitive edge of American businesses by lowering the corporate tax rate, eliminating loopholes and reducing paperwork to one page, making the tax code simple, easy, and fair, and returning trillions of dollars in wealth parked overseas to the American economy.
Vice President Mike Pence traveled to Buffalo, New York, on Tuesday to talk about the Administration’s America first tax relief plan with local businesses, community leaders, and families. The current tax code is broken and burdensome on American taxpayers and job-creators. The new plan will provide middle-class tax relief by permanently reducing tax rates, restoring the competitive edge of American businesses by lowering the corporate tax rate, eliminating loopholes and reducing paperwork to one page, making the tax code simple, easy, and fair, and returning trillions of dollars in wealth parked overseas to the American economy.
Learn more about how this vital tax relief will strengthen the middle class, grow the economy, and unleash America’s economic comeback.
Prime Minister of Greece Visits the White House
On Tuesday afternoon, President Trump welcomed the Prime Minister of Greece, Alexis Tsipras, to the White House. After a working luncheon, the two leaders held a joint press conference in the Rose Garden. Both leaders remarked on the strong, historic relationship that Greece and the United States share.
On Tuesday afternoon, President Trump welcomed the Prime Minister of Greece, Alexis Tsipras, to the White House. After a working luncheon, the two leaders held a joint press conference in the Rose Garden. Both leaders remarked on the strong, historic relationship that Greece and the United States share.
“A strong and flourishing Greece provides immense opportunity for American trade, investment, and job creation,” said President Trump.
Prime Minister Tsipras expressed his gratitude for the invitation to the White House and spoke of the nations’ relationship in light of recent and historical partnerships. “Today, our strategy is based on mutual respect, and it is fed by the significant support provided by the U.S. to Greece and to the Greek people during the hard times of the economic crisis,” he said.
PHOTO OF THE DAY
President Donald J. Trump in the Oval Office | October 17, 2017 (Official White House Photo by D. Myles Cullen)
POTUS TODAY
Today, President Trump recieved his daily intelligence briefng and spoke with Governor Kim Reynolds of Iowa by telephone. Later, the President participated in a meeting with the bipartisan group of Senators from the Senate Finance Committee to discuss the tax cuts and reform, and stressed the urgent need to deliver tax relief to the American people.
COMING UP
On Friday, First Lady Melania Trump will be joined by designer Hervé Pierre at the Smithsonian to present her inauguration gown as the newest addition to the nearly 100-year old First Ladies Collection.
Over the weekend, the White House will be opening its gardens and grounds to visitors for the Fall Garden Tours. Read more.
-----------------------------------------------------------------------
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
--------------------------------------------------------------------------
The Federal Trade Commission has announced an agenda for its upcoming workshop on competition issues related to prescription drug markets. The workshop, titled “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics,” will take place on November 8, 2017 at the FTC’s Constitution Center Auditorium, 400 7th St., SW, Washington, DC. The event begins at 8:30 a.m.
Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and Drug Commissioner Dr. Scott Gottlieb will give the keynote addresses.
The first session of the workshop will explore generic drug markets, including considerations that may preclude entry after relevant patents have expired. Panelists will discuss price and non-price factors that may influence entry in these markets. The second session will evaluate intermediaries in the pharmaceutical supply chain, focusing on pharmacy benefit managers (PBMs) and group purchasing organizations (GPOs). Panelists will discuss how the contractual relationships between intermediaries, manufacturers and health plan sponsors ultimately affect the prices consumers pay for prescription drugs. Throughout the day, speakers will discuss means to encourage entry and eliminate competitive impediments in prescription drug markets.
To help promote discussion on these questions, the FTC is inviting comments on a variety of questions including:
Do generic drug manufacturers have sufficient incentives to enter markets where the brand drug is off-patent? Do policymakers or market participants have a role in providing incentives to encourage entry decisions that better align with the public interest?
Some report strategies to reduce generic drug competition when the branded drug is off-patent. Are these reports accurate? If so, what steps are taken to reduce competition? If not, are there other reasons why generic entry is not seen as robust? What can be done?
What role do intermediaries, such as pharmacy benefit managers (PBMs) and group purchasing organizations (GPOs) play in prescription drug pricing, consumer access, and quality? What are the benefits and costs of intermediaries in the pharmaceutical supply chain? Has consolidation affected price, access, or quality?
How do companies assess the benefits, costs, and risks of contracting with intermediaries? How well do consumers understand intermediaries’ roles? Is more information necessary?
How should stakeholders evaluate proposals to reduce drug prices and increase consumer access in prescription drug markets? What role can the FTC play in addressing these issues?
The workshop is free and open to the public, and will be webcast live on the FTC’s website. Registration information, an agenda, directions to the FTC Conference Center and a list of speakers are available on the event web page. Advance registration is not required, but is strongly encouraged.
The Federal Trade Commission develops policy initiatives on issues that affect competition, consumers, and the U.S. economy. Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.
Statement of Acting FTC Chairman Maureen K. Ohlhausen on First Annual Review of EU-U.S.-Privacy Shield
Acting Federal Trade Commission Chairman Maureen K. Ohlhausen has issued the following statement regarding the release of the European Commission’s Report on the first annual review of the EU-U.S. Privacy Shield Framework.
“We welcome the positive outcome of the first EU-U.S. Privacy Shield Annual Review. Enforcing international privacy frameworks such as Privacy Shield is an integral part of our Privacy and Data Security program, as highlighted in three recently announced Privacy Shield enforcement actions. We look forward to continuing to work with our European counterparts to ensure that the Privacy Shield remains a robust mechanism for protecting privacy and enabling transatlantic data flows.”
For more information on the FTC’s enforcement of the Privacy Shield Framework please see the FTC’s Privacy Shield Page.
The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about consumer topics and file a consumer complaint online or by calling 1-877-FTC-HELP (382-4357). Like the FTC on Facebook, follow us on Twitter, read our blogs and subscribe to press releases for the latest FTC news and resources.
The Federal Trade Commission has announced an agenda for its upcoming workshop on competition issues related to prescription drug markets. The workshop, titled “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics,” will take place on November 8, 2017 at the FTC’s Constitution Center Auditorium, 400 7th St., SW, Washington, DC. The event begins at 8:30 a.m.
Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and Drug Commissioner Dr. Scott Gottlieb will give the keynote addresses.
The first session of the workshop will explore generic drug markets, including considerations that may preclude entry after relevant patents have expired. Panelists will discuss price and non-price factors that may influence entry in these markets. The second session will evaluate intermediaries in the pharmaceutical supply chain, focusing on pharmacy benefit managers (PBMs) and group purchasing organizations (GPOs). Panelists will discuss how the contractual relationships between intermediaries, manufacturers and health plan sponsors ultimately affect the prices consumers pay for prescription drugs. Throughout the day, speakers will discuss means to encourage entry and eliminate competitive impediments in prescription drug markets.
To help promote discussion on these questions, the FTC is inviting comments on a variety of questions including:
Do generic drug manufacturers have sufficient incentives to enter markets where the brand drug is off-patent? Do policymakers or market participants have a role in providing incentives to encourage entry decisions that better align with the public interest?
Some report strategies to reduce generic drug competition when the branded drug is off-patent. Are these reports accurate? If so, what steps are taken to reduce competition? If not, are there other reasons why generic entry is not seen as robust? What can be done?
What role do intermediaries, such as pharmacy benefit managers (PBMs) and group purchasing organizations (GPOs) play in prescription drug pricing, consumer access, and quality? What are the benefits and costs of intermediaries in the pharmaceutical supply chain? Has consolidation affected price, access, or quality?
How do companies assess the benefits, costs, and risks of contracting with intermediaries? How well do consumers understand intermediaries’ roles? Is more information necessary?
How should stakeholders evaluate proposals to reduce drug prices and increase consumer access in prescription drug markets? What role can the FTC play in addressing these issues?
The workshop is free and open to the public, and will be webcast live on the FTC’s website. Registration information, an agenda, directions to the FTC Conference Center and a list of speakers are available on the event web page. Advance registration is not required, but is strongly encouraged.
The Federal Trade Commission develops policy initiatives on issues that affect competition, consumers, and the U.S. economy. Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.
Statement of Acting FTC Chairman Maureen K. Ohlhausen on First Annual Review of EU-U.S.-Privacy Shield
Acting Federal Trade Commission Chairman Maureen K. Ohlhausen has issued the following statement regarding the release of the European Commission’s Report on the first annual review of the EU-U.S. Privacy Shield Framework.
“We welcome the positive outcome of the first EU-U.S. Privacy Shield Annual Review. Enforcing international privacy frameworks such as Privacy Shield is an integral part of our Privacy and Data Security program, as highlighted in three recently announced Privacy Shield enforcement actions. We look forward to continuing to work with our European counterparts to ensure that the Privacy Shield remains a robust mechanism for protecting privacy and enabling transatlantic data flows.”
For more information on the FTC’s enforcement of the Privacy Shield Framework please see the FTC’s Privacy Shield Page.
The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about consumer topics and file a consumer complaint online or by calling 1-877-FTC-HELP (382-4357). Like the FTC on Facebook, follow us on Twitter, read our blogs and subscribe to press releases for the latest FTC news and resources.
-------------------------------------------------------
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου